Yoshiteru Takekita

List of Publications by Year
in descending order

39 papers	825 citations	567144 15 h-index	501076 28 g-index
44 all docs	44 docs citations	44 times ranked	1237 citing authors

#	Article	IF	Citations
1	Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. CNS Spectrums, 2022, 27, 369-377.	0.7	2
2	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. World Journal of Biological Psychiatry, 2022, 23, 785-793.	1.3	6
3	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International Journal of Molecular Sciences, 2022, 23, 3873.	1.8	8
4	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. Journal of Affective Disorders, 2022, 314, 27-33.	2.0	4
5	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first‐episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. Human Psychopharmacology, 2021, 36, e2804.	0.7	5
6	Sevoflurane in electroconvulsive therapy: A systematic review and meta-analysis of randomised trials. Journal of Psychiatric Research, 2021, 141, 16-25.	1.5	3
7	Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2871-2879.	1.0	0
8	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 2019, 209, 50-57.	1.1	27
9	Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder. Neuropsychobiology, 2019, 78, 136-144.	0.9	4
10	Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder. BJPsych Open, 2018, 4, 454-460.	0.3	2
11	Sevoflurane anesthesia in electroconvulsive therapy: a meta-analysis of randomized controlled trials. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-90.	0.0	0
12	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research, 2017, 89, 97-104.	1.5	17
13	Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. Neuropsychobiology, 2017, 75, 81-88.	0.9	19
14	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv125.	1.0	26
15	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry, 2016, 16, 172.	1.1	16
16	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. Evidence-Based Mental Health, 2016, 19, e25-e25.	2.2	0
17	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 27-31.	0.7	11
18	Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 703-717.	1.8	24

#	Article	IF	Citations
19	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology, 2016, 73, 35-42.	0.9	21
20	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. Neuropsychobiology, 2015, 72, 118-125.	0.9	8
21	Case of adultâ€onset type <scp>II</scp> citrullinemia treated as schizophrenia for a long time. Psychiatry and Clinical Neurosciences, 2015, 69, 306-307.	1.0	8
22	Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 414-423.	0.6	7
23	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 220-227.	0.7	22
24	Antagonist and partial agonist at the dopamine D2 receptors in drug-naÃ¯ve and non-drug-naÃ¯ve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 579-588.	1.8	5
25	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational Psychiatry, 2015, 5, e513-e513.	2.4	20
26	A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 110-114.	2.5	13
27	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2013, 33, 131-132.	0.7	12
28	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2012, , 1.	0.7	1
29	Differences in quantitative EEG between frontotemporal dementia and Alzheimerâ€™s disease as revealed by LORETA. Clinical Neurophysiology, 2011, 122, 1718-1725.	0.7	69
30	Olfactory reference syndrome treated by blonanserin augmentation. Psychiatry and Clinical Neurosciences, 2011, 65, 203-204.	1.0	3
31	Syndrome of inappropriate secretion of antiâ€diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. International Journal of Geriatric Psychiatry, 2010, 25, 433-434.	1.3	9
32	Effect of 5â€HT1A gene polymorphisms on antidepressant response in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 115-123.	1.1	89
33	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European Neuropsychopharmacology, 2009, 19, 718-725.	0.3	24
34	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 398-404.	2.5	126
35	Antidepressant response and intolerance to SSRI is not influenced by G-protein Î²3 subunit gene C825T polymorphism in Japanese major depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1041-1044.	2.5	29
36	The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran. Journal of Clinical Psychopharmacology, 2008, 28, 518-524.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Delirium Associated with Paroxetine in an Elderly Depressive Patient: A Case Report. Pharmacopsychiatry, 2007, 40, 199-200.	1.7	8
38	Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. Neuropsychobiology, 2006, 53, 186-195.	0.9	143
39	A series of case reports on abnormal sensation on eye movement associated with paroxetine discontinuation. International Clinical Psychopharmacology, 2006, 21, A29-A30.	0.9	3